{"i": ["Statistic PBO", "naloxone", "crushed eluxadoline", "eluxadoline .", "PBO lactose", "placebos", "intranasal oxycodone", "eluxadoline", "oxycodone hydrochloride immediate release", "morphine derivatives", "OXY IR , oxycodone", "control oxycodone .", "Parameter Statistic PBO", "Oxycodone", "placebo eluxadoline .", "OXY IR", "placebo .", "placebos matched to eluxadoline and oxycodone", "oxycodone", "placebo and oxycodone", "OXY", "matching placebo tablets", "placebo -", "ELX", "loperamide", "butorphanol", "\u03b4 - OR antagonist eluxadoline", "placebo lactose , weight matched to oxycodone , and placebo to match eluxadoline", "placebo", "PBO , placebo", "Eluxadoline", "placebo eluxadoline", "saline", "oxycodone , hydrocodone", "oxycodone .", "morphine", "placebo - controlled", "Intranasal Eluxadoline", "pentazocine", "crushed oxycodone hydrochloride", "eluxadoline and oxycodone", "oxycodone and eluxadoline", "PBO ELX", "placebo lactose"], "o": ["Any Effects VAS Emax score", "subjective pharmacodynamic ( PD )", "Drug Liking VAS", "jugular vein blood", "pupil diameter", "Subjective Opiate Withdrawal Scale", "Overall Drug Liking VAS", "Drug Liking Visual Analog Scale ( VAS ) peak ( maximum ) effect ( Emax ) score", "Subjective Drug Value .", "PK and PD", "Drug Similarity VAS mean scores for codeine / morphine , heroin , benzodiazepines , and pseudoephedrine", "events of feeling drunk", "High VAS score", "oral and intranasal abuse potential", "LS mean Emax score", "facial pain / pressure and nasal congestion .", "Take Drug Again VAS", "High VAS and Good Effects VAS", "Drug Liking VAS peak ( minimum ) effect ( Emin ) scores", "Adverse events ( AEs )", "Effects VAS Emax scores", "Drug Liking VAS Emax )", "mean pupil diameter", "relative exposure", "behavioral changes", "LS mean score", "Drug Liking Emin scores", "median Emax scores", "Least squares ( LS ) mean Emin scores", "withdrawal", "Drug Liking Visual Analog Scale ( VAS ),", "Drug Liking VAS Emax", "Mean pupil diameter", "need to blow nose and runny nose / nasal discharge", "Mean Emax scores", "Adverse events of euphoric mood", "burning", "AEs of euphoric mood", "observer - rated nasal effects scale Emax scores", "Emax scores", "central effects", "intranasal irritation and percentage of dose insufflated", "opiate withdrawal AEs", "Any Effects VAS Emax scores", "Drug Liking VAS Emax score", "mean scores", "abuse - related AEs", "mean and range of peak responses", "Drug Similarity VAS", "Median scores", "Bad Effects VAS Emax", "oral bioavailability", "nasal congestion , nasal irritation , and nasal discharge", "binding affinity", "Drug Liking VAS Emax scores", "Addiction Research Center Inventory ( ARCI ) Morphine Benzedrine Group scale .", "median difference", "Drug Liking scores", "insufflation", "subject - rated nasal effects", "Scores", "Mean Bad Effects VAS Emax scores", "Good Effects VAS score", "Drug Liking VAS peak ( maximum ) effect ( Emax", "miosis", "Mean scores for subject - rated nasal effects", "euphoric mood", "eluxadoline plasma concentrations", "abuse potential ( euphoric mood , somnolence , dizziness , fatigue ), somnolence and fatigue", "ARCI Lysergic Acid Diethylamide Group scale .", "VAS scores", "percentage of dose insufflated", "median scores", "Mean Cmax", "Pupillometry", "dizziness", "Alertness / Drowsiness VAS Emin scores", "median time to Cmax [ time to maximum observed plasma concentration ( Tmax )]", "mean Emin score", "Euphoric mood", "abuse potential", "adverse nasal effects", "Bad Effects VAS", "Good Effects VAS and High VAS Emax scores", "systemic levels", "ARCI Phenobarbital - Chlorpromazine - Alcohol Group scale .", "mean numbers of instances of opioid usage", "Mean scores", "Alertness / Drowsiness VAS", "LS mean scores", "codeine / morphine scale", "intranasal opioid use", "Median Tmax", "disliking", "Any Effects VAS ( unipolar", "nasal irritation"]}